Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortIL-17A antibody for psoriasis and spondyloarthritis.Biologic for psoriasis and spondyloarthritis.
Body systemJoints & ImmunityJoints & Immunity
Drug classInterleukin inhibitorsInterleukin inhibitors
SupplyPrescription onlyPrescription only
Main usesPlaque psoriasis, Psoriatic arthritis, Ankylosing spondylitisPlaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis, Hidradenitis suppurativa
How it worksBlocks inflammation signal IL-17A.Blocks an inflammation signal central to psoriasis.
Starts workingWeeks—
Half-lifeAbout 13 daysAbout 27 days
Typical adult dose160 mg once, then 80 mg every 2 weeks to week 12, then every 4 weeks (psoriasis).300 mg weekly for 5 weeks, then every 4 weeks.
FormsSubcutaneous injectionPre-filled pen, IV infusion
Common side effectsInjection site reactions, Upper respiratory infections, Nausea, Fungal skin infectionsCold-like infections, Oral thrush, Diarrhoea
Serious side effectsSerious infections, Inflammatory bowel disease flares, Severe allergic reactionsNew or worse inflammatory bowel disease, Serious infections
Don't take ifActive serious infection; Active TB; Inflammatory bowel disease (caution)—
AlcoholUsually no problem in moderation. No specific interaction.—
PregnancyUse with cautionLimited data.Use with cautionLimited data.
BreastfeedingUse with cautionLimited data.—
In use since—2015
Brand namesUnited States: TaltzUnited Kingdom: TaltzIndia: TaltzUnited States: CosentyxUnited Kingdom: CosentyxIndia: Scapho
Legal statusUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H—
ATC codeL04AC13L04AC10

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker